ArticleJTO clinical and research reports2022

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced

Dong-Wan Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.